We are a life science venture capital investor, delivering knowledge, network, and capital to companies.
Novo Holdings A/S
Tuborg Havnevej 19
+45 3527 6500
Novo Ventures (US) Inc.*
1700 Owens Street, Suite 540
San Francisco, CA 94158
+1 (415) 552-6686
Novo Ventures (US) Inc.*
200 Clarendon Street, Floor 45
Boston, MA 02142
*Novo Ventures (US) Inc. is a separate legal entity that provides certain consultancy services to Novo Holdings A/S, mainly within the areas of identifying, analysing and negotiating various investment opportunities among life science and biotech companies in the US as well as certain follow-up activities related thereto, such as board memberships, financial control and reporting efforts.
What we do
Our approach to venture investments
We strive to invest in companies that develop innovative drugs, medical devices and diagnostics that can potentially improve the health and welfare of people around the world.
We focus on building and realizing strong financial returns from our portfolio of venture companies.
With people on the ground in Copenhagen, London, San Francisco and Boston, we are well positioned in the major global life science hubs and can quickly respond to new and exciting investment opportunities wherever they emerge.
We primarily invest in biotechnology and medical technology. Within biotech we primarily invest in companies with clinical stage compounds. In medtech, we invest in commercial stage companies.
We invest in both private and public companies from an open evergreen fund with Novo Holdings as the only investor. This funding structure enables us to assume a long-term perspective.
We work actively with the companies we invest in by serving on the Boards of Directors. Companies can also draw on our extensive network, as well as our commercial and scientific expertise within the life sciences.
During our past 10 years in the business, we have invested DKK 10 billion in 130 companies and successfully exited 46 companies – primarily through sales to large pharmaceutical and medical device companies, and through IPOs.
In the years to come, we will continue to expand our venture investments in both private and public companies, and we will continue to focus on development- and regulatory-stage companies that address unmet therapeutic needs.
Meet our staff
We are a focused team with streamlined decision making and we are quick to respond to investment opportunities when they arise.
With professionals based out of Copenhagen, San Francisco, Boston and London and an international network of commercial and scientific specialists, our team is geared to reach the major hubs of life science.
Over the past 10 years
€ 1.3 bn